NATCO Pharma Ltd reported a 37.75 per cent decline in consolidated net profit to ₹132.4 crore for Q3 FY2025, down from ₹212.7 crore in the same quarter last year. The company’s shares plummeted 17.28 per cent to ₹1,008.25 on the NSE, touching a 52-week low of ₹829.60.
The pharmaceutical company’s consolidated revenue from operations fell 37.4 per cent to ₹474.8 crore, compared to ₹758.6 crore in Q3 FY2024. EBITDA witnessed a sharp decline of 85.5 per cent to ₹38.8 crore, with margins contracting by 2,717 basis points to 8.2 per cent.
- Read also: Jubilant FoodWorks Q3 net ₹43.2 crore, revenue surges 56%
The earnings downturn was primarily attributed to weak formulation exports, which decreased to ₹285.8 crore from ₹605.6 crore year-over-year. Domestic formulation sales also dipped to ₹96.1 crore from ₹99.4 crore in the corresponding period.
Despite reduced total expenses at ₹487.4 crore compared to ₹539.3 crore last year, the company’s performance remained under pressure due to weak revenue generation.
Separately, the board declared a third interim dividend of ₹1.50 per equity share for FY2024-25, with February 18, 2025, set as the record date. The dividend payment is scheduled to commence from February 28, 2025.
